Cancer Biologics Market (By Drug Class: Monoclonal Antibodies, Cancer Growth Inhibitors, Vaccines, Recombinants Proteins, CAR-T Cells, Angiogenesis Inhibitors, Interleukins, Interferons, Gene Therapy, Others; By Applications: Blood Cancer, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Gastric Cancer, Ovarian Cancer, Skin Cancer, Liver Cancer, Others; By End-use) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2034
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cancer Biologics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cancer Biologics Market, by Drug Class, 2024-2034
8.1.1 Monoclonal Antibodies
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Cancer Growth Inhibitors
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Vaccines
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Recombinants Proteins
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. CAR-T Cells
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Angiogenesis Inhibitors
8.1.6.1. Market Revenue and Forecast (2021-2034)
8.1.7. Interleukins (IL)
8.1.7.1. Market Revenue and Forecast (2021-2034)
8.1.8. Interferons (IFN)
8.1.8.1. Market Revenue and Forecast (2021-2034)
8.1.9. Gene Therapy
8.1.9.1. Market Revenue and Forecast (2021-2034)
8.1.10. Others
8.1.10.1. Market Revenue and Forecast (2021-2034)
9.1. Cancer Biologics Market, by Applications, 2024-2034
9.1.1. Blood Cancer
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Lung Cancer
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Breast Cancer
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Colorectal Cancer
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Prostate Cancer
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Gastric Cancer
9.1.6.1. Market Revenue and Forecast (2021-2034)
9.1.7. Ovarian Cancer
9.1.7.1. Market Revenue and Forecast (2021-2034)
9.1.8. Skin Cancer
9.1.8.1. Market Revenue and Forecast (2021-2034)
9.1.9. Liver Cancer
9.1.9.1. Market Revenue and Forecast (2021-2034)
9.1.10. Others
9.1.10.1. Market Revenue and Forecast (2021-2034)
10.1. Cancer Biologics Market, by End use, 2024-2034
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Cancer Center
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Academics & Research Institutes
10.1.3.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.1.2. Market Revenue and Forecast, by Applications (2021-2034)
11.1.3. Market Revenue and Forecast, by End use (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Applications (2021-2034)
11.1.4.3. Market Revenue and Forecast, by End use (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Applications (2021-2034)
11.1.5.3. Market Revenue and Forecast, by End use (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.2. Market Revenue and Forecast, by Applications (2021-2034)
11.2.3. Market Revenue and Forecast, by End use (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Applications (2021-2034)
11.2.4.3. Market Revenue and Forecast, by End use (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Applications (2021-2034)
11.2.5.3. Market Revenue and Forecast, by End use (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Applications (2021-2034)
11.2.6.3. Market Revenue and Forecast, by End use (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Applications (2021-2034)
11.2.7.3. Market Revenue and Forecast, by End use (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.2. Market Revenue and Forecast, by Applications (2021-2034)
11.3.3. Market Revenue and Forecast, by End use (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Applications (2021-2034)
11.3.4.3. Market Revenue and Forecast, by End use (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Applications (2021-2034)
11.3.5.3. Market Revenue and Forecast, by End use (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Applications (2021-2034)
11.3.6.3. Market Revenue and Forecast, by End use (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Applications (2021-2034)
11.3.7.3. Market Revenue and Forecast, by End use (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.2. Market Revenue and Forecast, by Applications (2021-2034)
11.4.3. Market Revenue and Forecast, by End use (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Applications (2021-2034)
11.4.4.3. Market Revenue and Forecast, by End use (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Applications (2021-2034)
11.4.5.3. Market Revenue and Forecast, by End use (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Applications (2021-2034)
11.4.6.3. Market Revenue and Forecast, by End use (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Applications (2021-2034)
11.4.7.3. Market Revenue and Forecast, by End use (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.5.2. Market Revenue and Forecast, by Applications (2021-2034)
11.5.3. Market Revenue and Forecast, by End use (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Applications (2021-2034)
11.5.4.3. Market Revenue and Forecast, by End use (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Applications (2021-2034)
11.5.5.3. Market Revenue and Forecast, by End use (2021-2034)
12.1. Abbott
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Angel
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Amgen, Inc
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. AstraZeneca
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. BioNTech
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Bristol-Mayer Squibb Company
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Dr. Reddy's Laboratories
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Duality Biologics
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Eli Lilly and Company
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. F.Hoffmann-La Roche Ltd.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample